The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Improving CAR-T functionality with CELMoDs in multiple myeloma
In this video, Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, briefly comments on the potential of using cereblon E3 ligase modulators (CELMoDs) to improve CAR-T functionality in multiple myeloma (MM). Dr Parekh highlights that in a study of patients treated with iberdomide, higher NK and T-cell activation, improved CAR-T persistence, and enhanced killing activity were observed. This suggests that repurposing CELMoDs to enhance CAR-T activity could improve outcomes for patients with variable responses to CAR T-cell therapy. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
In collaboration with colleagues at Oxford, Udo Oppermann and Anjan Thakurta, we had done a large-scale study using CyTOF on over 100 patients and found that the CELMoD CC-220, or iberdomide, improved NK and T-cell activation, and this was in the bone marrow of patients in the Phase I/II study as part of an international consortium. We have since then been able to show that the CELMoDs can actually improve the CAR-T persistence as well as killing activity and this indicates an important way that repurposing CELMoDs to improve CAR-T activity would be an easy way to actually help our patients that are having variable outcomes get even better outcomes from CAR-T...
In collaboration with colleagues at Oxford, Udo Oppermann and Anjan Thakurta, we had done a large-scale study using CyTOF on over 100 patients and found that the CELMoD CC-220, or iberdomide, improved NK and T-cell activation, and this was in the bone marrow of patients in the Phase I/II study as part of an international consortium. We have since then been able to show that the CELMoDs can actually improve the CAR-T persistence as well as killing activity and this indicates an important way that repurposing CELMoDs to improve CAR-T activity would be an easy way to actually help our patients that are having variable outcomes get even better outcomes from CAR-T.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
